Search Clinical Trials

30 Results

Active, Not Recruiting
Post IVIG Medication in Children With Immune Thrombocytopenia (External Link)
Immune thrombocytopenia (ITP) is the most common acquired immune cytopenia in childhood, affecting 4-6 in 100,000 children. The pathophysiology of ITP is highly complex and incompletely understood. Accepted mechanisms include …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine (External Link)
The vaccine will be administered orally (by mouth) as a solution mixed with sodium bicarbonate. Approximately 10 minutes prior to receiving the vaccine, participants will take sodium bicarbonate pills to …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Glutathione, Oxidative Stress and Mitochondrial Function in COVID-19 (External Link)
This study will investigate associated defects in the following two populations of patients with COVID-19: Hospitalized patients admitted for COVID-19 will sign an informed consent form, and be randomized to …
Baylor Role: Lead Sponsor
Active, Not Recruiting
BCG Vaccine for Health Care Workers as Defense Against COVID 19 (External Link)
Study design: A placebo-controlled adaptive multi-center randomized controlled trial. Study population: High risk HCW with direct patient contacts, defined as physician assistants, respiratory therapists, nurses, physicians or other HCWs working …
Baylor Role: Collaborator
Active, Not Recruiting
Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults (External Link)
The study will recruit up to 290 healthy adult males and non-pregnant females into a two-part clinical trial of a vaccine to protect against schistosomiasis caused by infection with S. …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children (External Link)
This is a prospective, open label, randomized, two-arm, multi-center Phase 3 trial. Patients with newly diagnosed ITP are randomized 2:1 to receive the experimental treatment, eltrombopag, or investigator's choice of …
Baylor Role: Lead Sponsor
Active, Not Recruiting
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) (External Link)
To prepare the T cells (GD2-C7R T cells), research staff will take some blood from the patient. We will grow the GD2.C7R T cells by infecting the T cells with …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) (External Link)
Approximately 18-30 subjects will participate in the treatment part of this study. Maximum of 180 mL of blood (not exceeding 3ml/kg/day) is collected from patients to grow the T cells …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML) (External Link)
Standard cytotoxic chemotherapy is based on the Medical Research Council (MRC) backbone of cytarabine, and daunorubicin. This combination of chemotherapy is highly myelosuppressive and can lead to oral aversions, dietary …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection (External Link)
Double blind, randomized, controlled, Phase 2 clinical trial in hookworm-unexposed adults living in the metropolitan area of Washington, DC. Subjects will receive three doses of the assigned vaccine formulation, or …
Baylor Role: Lead Sponsor